Kathiawad Today

Diabetic Foot Ulcer Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Diabetic Foot Ulcer Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 23
18:40 2023
Diabetic Foot Ulcer Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Diabetic Foot Ulcer Pipeline Insights
DelveInsight’s ‘Diabetic Foot Ulcer Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Foot Ulcer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Foot Ulcer pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Diabetic Foot Ulcer Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Foot Ulcer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Foot Ulcer pipeline domain.

Key Takeaways from the Diabetic Foot Ulcer Pipeline Report

  • Over 34+ Diabetic Foot Ulcer pipeline therapies are in various stages of development, and their anticipated acceptance in the Diabetic Foot Ulcer market would significantly increase market revenue. 
  • Leading Diabetic Foot Ulcer companies developing novel drug candidates to improve the Diabetic Foot Ulcer treatment landscape include Aurealis Therapeutics, Charsire Biotechnology Corporation, and others.
  • Promising Diabetic Foot Ulcer pipeline therapies in various stages of development include AUP 16, CSTC 1, and others.

Diabetic Foot Ulcer Overview

A Diabetic Foot Ulcerss is an open sore or wound that occurs among the most common complications of patients who have diabetes mellitus which is not well controlled. Diabetic ulcers are the most common foot injuries leading to lower extremity amputation. The most common risk factors for ulcer formation include diabetic neuropathy, structural foot deformity and peripheral arterial occlusive disease. The primary goal in the treatment of foot ulcers is to obtain healing as soon as possible. The management of Diabetic Foot Ulcersss requires offloading the wound, daily saline or similar dressings to provide a moist wound environment, debridement when necessary, antibiotic administration with or without surgical intervention if osteomyelitis or soft tissue infection is present, optimal control of blood glucose, and evaluation and correction of peripheral arterial insufficiency.

Diabetic Foot Ulcer Pipeline Analysis: Drug Profile

AUP 16: Aurealis Therapeutics

AUP-16 is a safe and effective recombinant live biotherapeutic product that features a patented active bacterial vector containing three therapeutic proteins (FGF2, IL4, and CSF1), produced continuously at the site of the wound, providing a combination biologic treatment in one product.

Discover more about the emerging Diabetic Foot Ulcer drugs @ Diabetic Foot Ulcer Treatment Drugs

Diabetic Foot Ulcer Key Companies

  • Aurealis Therapeutics
  • Charsire Biotechnology Corporation

Diabetic Foot Ulcer Pipeline Therapies

  • AUP 16
  • CSTC 1

Diabetic Foot Ulcer Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Diabetic Foot Ulcer Pipeline Report 

  • Coverage: Global 
  • Key Diabetic Foot Ulcer Companies: Aurealis Therapeutics, Charsire Biotechnology Corporation, and others
  • Key Diabetic Foot Ulcer Pipeline Therapies: AUP 16, CSTC 1, and others

Find out more about the Diabetic Foot Ulcer treatment options in development @ Diabetic Foot Ulcer Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Diabetic Foot Ulcer pipeline domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/